2017
DOI: 10.1007/s10067-017-3652-3
|View full text |Cite|
|
Sign up to set email alerts
|

Expression of CCR6 on B cells in systemic lupus erythematosus patients

Abstract: B cells are known to play a dominant pathogenic role in autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. In recent times, the chemokine receptor CCR6 and its cognate ligand CCL20 have been shown to play a role in the fundamental kinetics of germinal centres and B cell responses. As CCR6 is found on B cells and is upregulated after activation, we investigated the expression of CCR6 on naive, pre-germinal centre (GC), GC/plasma cell and memory B cells in peripheral B cel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
2

Year Published

2018
2018
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 12 publications
(12 citation statements)
references
References 16 publications
0
10
2
Order By: Relevance
“…Although the major B-cell subsets were found not to differ between SLE patients and HCs, CCR6 was found to be more prominently expressed on B cells of SLE patients compared with HCs. 66 This is in contrast to a previous study that did not establish any difference between CCR6 across B cells and their subsets. 67 Diagnostic utility of CCR6-CCL20 in SLE The search for biomarkers for diagnosis, prognosis and monitoring treatment remains a significant part of medical research in diseases.…”
Section: B Cellscontrasting
confidence: 88%
See 1 more Smart Citation
“…Although the major B-cell subsets were found not to differ between SLE patients and HCs, CCR6 was found to be more prominently expressed on B cells of SLE patients compared with HCs. 66 This is in contrast to a previous study that did not establish any difference between CCR6 across B cells and their subsets. 67 Diagnostic utility of CCR6-CCL20 in SLE The search for biomarkers for diagnosis, prognosis and monitoring treatment remains a significant part of medical research in diseases.…”
Section: B Cellscontrasting
confidence: 88%
“…CCR6 and CCL20 may assist with positioning T FH and B cells at the T-B cell border and contributing to the "quality" of the T-B cell synapse. 8 The role of the possible raised CCR6 on B-cell subsets in SLE patients 66 remains a mystery at this stage. However, Elgueta et al 75 have shown that CCR6 expression on memory B cells remains important for proper localization and function of these cells in lymphoid organs, and CCR6 has been identified as a marker of B cells undergoing memory B-cell differentiation.…”
Section: Discussionmentioning
confidence: 99%
“…Here, viSNE maps from patients and controls did not show the same pattern, suggesting a reorganisation of B cell subpopulations after septic shock. To further investigate this observation, cells were coloured on viSNE plots according to cell surface expression of CD38 or CCR6, two markers of B cell differentiation 13 . We observed that, in both healthy donors and septic shock patients, CD38 + and CCR6 + cells did not present same location on the viSNE map, indicating that they belonged to different cell subtypes.…”
Section: Resultsmentioning
confidence: 99%
“…IGHM is down-regulated in colorectal cancer and idiopathic pulmonary fibrosis (Yang et al, 2012;Pentheroudakis et al, 2015). CCR6 is highly expressed in the B cells of SLE patients (Lee et al, 2017) and colon cancer patients (Kapur et al, 2016); RASGRP3 is highly expressed in breast cancer (Nagy et al, 2012), glioblastoma (Lee et al, 2015), prostate cancer (Zeng et al, 2014), uveal melanoma (Chen et al, 2017) and other malignant carcinomas. Overall, key genes are both age-related and disease-related and are expressed differentially relative to varying health conditions in the aging process.…”
Section: Discussionmentioning
confidence: 99%